Company Filing History:
Years Active: 2002
Title: Mark G Steiner: Innovator in Src Kinase Inhibitor Compounds
Introduction
Mark G Steiner is a notable inventor based in East Brunswick, NJ, whose contributions to medical chemistry have the potential to impact the treatment of various diseases significantly. With a focus on Src kinase inhibitor compounds, he has made strides in developing effective pharmaceutical compositions.
Latest Patents
Mark G Steiner holds a patent for Src kinase inhibitor compounds, specifically pyrimidine compounds. This invention, along with their pharmaceutically acceptable salts, hydrates, solvates, crystal forms, and individual diastereomers, focus on inhibiting tyrosine kinase enzymes. The implications of this patent are profound, as these compounds may offer therapeutic benefits in preventing and treating diseases associated with inappropriate protein kinase action, such as cancer, immune diseases, hyperproliferative disorders, and others including atherosclerosis, graft rejection, rheumatoid arthritis, and psoriasis.
Career Highlights
Steiner is currently associated with Merck & Company, Inc., a leading pharmaceutical firm known for its commitment to innovative healthcare solutions. Throughout his career, he has dedicated himself to advancing therapeutic strategies and enhancing patients' quality of life through scientific innovations.
Collaborations
In his endeavors at Merck, Mark has had the opportunity to collaborate with esteemed colleagues such as Helen M Armstrong and Richard Beresis. These partnerships have fostered a collaborative environment that promotes the sharing of ideas and expertise required to drive innovation in the pharmaceutical domain.
Conclusion
Mark G Steiner's work on Src kinase inhibitors represents a significant advancement in the field of medicinal chemistry. As diseases linked to protein tyrosine kinases become increasingly prevalent, his contributions are expected to play a crucial role in developing targeted therapies. His commitment to research and collaboration continues to inspire and influence the landscape of pharmaceutical innovation.